ArticleJournal of virology2014
Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model.
Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Viral vector-based influenza vaccines.Human vaccines & immunotherapeutics · 2016Pooled it
- Quantifying the role of pre-existing tissue resident cellular immunity in limiting respiratory virus transmission.PLoS pathogens · 2026Article
- Article
- Article
- Bacteria Are a Major Determinant of Orsay Virus Transmission and Infection inbioRxiv : the preprint server for biology · 2024Article
- Q fever immunology: the quest for a safe and effective vaccine.NPJ vaccines · 2023Review
- Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG.Pharmaceutics · 2023Article
- A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts.Human vaccines & immunotherapeutics · 2022Article
- Reduction of Influenza A Virus Transmission in Mice by a Universal Intranasal Vaccine Candidate is Long-Lasting and Does Not Require Antibodies.Journal of virology · 2022Article
- Influenza vaccine uptake among at-risk adults (aged 16-64 years) in the UK: a retrospective database analysis.BMC public health · 2021Article
- Article
- Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic.NPJ vaccines · 2021Review
- Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.Clinical & translational immunology · 2021Review
- Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines.Vaccines · 2020Review
- Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine.PLoS pathogens · 2020Review
- Influenza A virus is transmissible via aerosolized fomites.Nature communications · 2020Article
- Population implications of the deployment of novel universal vaccines against epidemic and pandemic influenza.Journal of the Royal Society, Interface · 2020Article
- Review
- Article
- Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo.American journal of epidemiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledPandemic influenza is a major public health concern, but conventional strain-matched vaccines are unavailable early in a pandemic. Candidate "universal" vaccines targeting the viral antigens nucleoprotein (NP) and matrix 2 (M2), which are conserved among all influenza A virus strains and subtypes, could be manufactured in advance for use at the onset of a pandemic. These vaccines do not prevent infection but can reduce disease severity, deaths, and virus titers in the respiratory tract. We hypothesized that such immunization may reduce virus transmission from vaccinated, infected animals. To investigate this hypothesis, we studied mouse models for direct-contact and airborne transmission of H1N1 and H3N2 influenza viruses. We established conditions under which virus transmission occurs and showed that transmission efficiency is determined in part at the level of host susceptibility to infection. Our findings indicate that virus transmission between mice has both airborne and direct-contact components. Finally, we demonstrated that immunization with recombinant adenovirus vectors expressing NP and M2 significantly reduced the transmission of virus to cohoused, unimmunized mice in comparison to controls. These findings have broad implications for the impact of conserved-antigen vaccines, not only in protecting the vaccinated individual but also in protecting others by limiting influenza virus transmission and potentially reducing the size of epidemics. IMPORTANCE: Using a mouse model of influenza A virus transmission, we demonstrate that a candidate "universal" influenza vaccine both protects vaccinated animals from lethal infection and reduces the transmission of virus from vaccinated to nonvaccinated mice. This vaccine induces immunity against proteins conserved among all known influenza A virus strains and subtypes, so it could be used early in a pandemic before conventional strain-matched vaccines are available and could potentially reduce the spread of infection in the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.